Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
ESET, LLC v. Finjan, Inc.
Case Number:
19-1716
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
May 15, 2020
COVID-19 IP Catch-Up: Source Code Woes, Generic Antivirals
The Federal Circuit will continue to hold remote oral arguments into the summer, Gilead is allowing some generic-drug makers to produce versions of its antiviral treatment remdesivir, and companies that are allegedly upcharging for coronavirus-related products are continuing to find themselves in court for trademark law violations.
-
May 11, 2020
Finjan Holds Onto Antivirus Patent In Fight With ESET
The Federal Circuit on Monday upheld a Patent Trial and Appeal Board decision that ESET LLC failed to prove that a Finjan computer antivirus patent is invalid, dismissing ESET's argument that it faced "undeserved prejudice" from the board, a claim Finjan called "simply nonsense."